DENTSPLY SIRONA (NASDAQ:XRAY) Raised to Hold at Zacks Research

DENTSPLY SIRONA (NASDAQ:XRAY) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other research firms also recently issued reports on XRAY. JPMorgan Chase & Co. dropped their target price on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research note on Wednesday, January 21st. Bank of America raised shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $13.00 to $17.00 in a research report on Thursday, February 19th. Robert W. Baird upped their price target on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. Finally, Mizuho raised their price objective on DENTSPLY SIRONA from $14.00 to $16.00 and gave the company a “neutral” rating in a research note on Monday. Three research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $14.42.

DENTSPLY SIRONA Stock Performance

XRAY stock opened at $13.30 on Monday. The firm has a market cap of $2.66 billion, a PE ratio of -4.43, a price-to-earnings-growth ratio of 1.68 and a beta of 0.97. The company has a current ratio of 1.51, a quick ratio of 1.03 and a debt-to-equity ratio of 1.50. The stock has a 50-day moving average price of $12.52 and a 200-day moving average price of $12.47. DENTSPLY SIRONA has a 1-year low of $9.85 and a 1-year high of $17.18.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The business had revenue of $961.00 million for the quarter, compared to analyst estimates of $926.40 million. During the same period in the prior year, the business earned $0.26 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts expect that DENTSPLY SIRONA will post 1.84 earnings per share for the current year.

Insider Buying and Selling

In other DENTSPLY SIRONA news, Director Gregory T. Lucier purchased 22,445 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were acquired at an average cost of $14.03 per share, for a total transaction of $314,903.35. Following the completion of the acquisition, the director owned 50,000 shares of the company’s stock, valued at $701,500. The trade was a 81.46% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.52% of the company’s stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

Large investors have recently made changes to their positions in the business. Virtu Financial LLC bought a new stake in shares of DENTSPLY SIRONA during the 4th quarter worth $302,000. Compound Planning Inc. purchased a new stake in DENTSPLY SIRONA during the fourth quarter worth about $117,000. Invesco Ltd. raised its position in DENTSPLY SIRONA by 101.1% in the fourth quarter. Invesco Ltd. now owns 1,063,523 shares of the medical instruments supplier’s stock worth $12,156,000 after acquiring an additional 534,714 shares during the period. Michels Family Financial LLC raised its position in DENTSPLY SIRONA by 8.9% in the fourth quarter. Michels Family Financial LLC now owns 41,989 shares of the medical instruments supplier’s stock worth $480,000 after acquiring an additional 3,422 shares during the period. Finally, Alpine Woods Capital Investors LLC purchased a new position in DENTSPLY SIRONA in the fourth quarter valued at about $680,000. 95.70% of the stock is owned by hedge funds and other institutional investors.

More DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Director buying: Gregory T. Lucier purchased 22,445 shares on March 3 (~$14.03) after buying 27,555 shares on March 2 (~$14.24), bringing his reported holdings to ~50,000 shares — a strong insider vote of confidence that often supports the share price. Director purchase – InsiderTrades
• Positive Sentiment: Barrington Research raised its price target to $17 and maintained an “outperform” rating — a meaningful upside call relative to current levels that can attract buying interest. Barrington Research PT Raise
• Positive Sentiment: Zacks upgraded XRAY from “strong sell” to “hold,” removing a strong negative label and supporting improved market sentiment. Zacks upgrade
• Neutral Sentiment: Mizuho lifted its price target to $16 but kept a “neutral” rating — a PT boost that helps sentiment but the unchanged rating tempers immediate buying pressure. Mizuho PT Update
• Neutral Sentiment: Investor access: Management will present at the Leerink Partners Global Healthcare Conference on March 10 — a potential near‑term catalyst if management provides incremental guidance or color. Conference Notice
• Neutral Sentiment: Short‑interest data in recent reports appears anomalous (reports show zero / NaN changes) — treat those short‑interest updates as reporting noise rather than a real short‑squeeze signal.
• Negative Sentiment: Recent fundamentals still show friction: Q4 report (Feb. 26) included a slight EPS miss ($0.27 vs. $0.28) and a negative net margin, reminders that profitability and margin recovery remain key risks for longer‑term upside. MarketBeat XRAY summary

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.